Blue Cross and Blue Shield of Texas Sponsors Bridges to Excellence Program, Focusing on Quality Management of Diabetes
Posted on: Monday, 23 March 2009, 11:43 CDT
Bold, new BCBSTX program to make health and wellness top priorities by rewarding physicians for performance.
"Blue Cross and Blue Shield of
Bridges to Excellence(R) is a not-for-profit company, founded in 2002, whose mission is to create significant progress in quality of care by recognizing and financially rewarding physicians who demonstrate that they provide quality care that meets established guidelines.
"Improving the management of patients with Diabetes and other chronic illnesses has been a priority for BCBSTX for years," says Francois deBrantes, Chief Executive Officer, Bridges to Excellence, "and, it's an honor for us to partner with Dr. Sanchez and his team to further stimulate the improvement in quality care for all residents in
Metabolic Syndrome
In addition to the BTE diabetes program, Blue Cross and Blue Shield of
About Blue Cross
Blue Cross and Blue Shield of
SOURCE Blue Cross and Blue Shield of
Source: PR Newswire
Related Articles
- CVAC Systems Expands Scientific Advisory Board, and Initiates Investigations into Diabetes, Insulin Resistance, and Metabolic Syndrome Applications
- CVAC Systems and TempusClinic Partner to Study the Potential Value of The CVAC Process in Managing and Treating Diabetes, Insulin Resistance, and Metabolic Syndrome
- Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated With the Metabolic Syndrome: A Summary of the Evidence
- Nicotinic Acid in the Management of Dyslipidaemia Associated With Diabetes and Metabolic Syndrome: a Position Paper Developed By a European Consensus Panel
- Cardiovascular Disease in U.S. Patients With Metabolic Syndrome, Diabetes, and Elevated C-Reactive Protein
- The Impact of Abnormalities in IGF and Inflammatory Systems on the Metabolic Syndrome
- Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Diasease?
- Metabolic Syndrome As a Predictor of All-Cause and Cardiovascular Mortality in Type 2 Diabetes: The Casale Monferrato Study
- Elevated Alanine Aminotransferase Predicts New-Onset Type 2 Diabetes Independently of Classical Risk Factors, Metabolic Syndrome, and C- Reactive Protein in the West of Scotland Coronary Prevention Study
- The Chemical Pathology of Insulin Resistance and the Metabolic Syndrome
User Comments (0)

RSS Feeds